X0306 4 2021-12-27 0 0001840574 Verve Therapeutics, Inc. VERV 0001864112 Kathiresan Sekar C/O VERVE THERAPEUTICS, INC. 500 TECHNOLOGY SQUARE, SUITE 901 CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer Common Stock 2021-12-27 4 M 0 42000 1.39 A 448536 D Common Stock 2021-12-27 4 S 0 36443 40.0228 D 412093 D Common Stock 2021-12-27 4 S 0 4787 41.2431 D 407306 D Common Stock 2021-12-27 4 S 0 770 42.2106 D 406536 D Common Stock 2021-12-28 4 M 0 6693 1.39 A 413229 D Common Stock 2021-12-28 4 S 0 6693 39.90 D 406536 D Common Stock 80997 I Kathiresan Family 2021 Irrevocable Trust Common Stock 80997 I Sekar Kathiresan 2021 Irrevocable Trust Stock Option (right to buy) 1.39 2021-12-27 4 M 0 42000 0.00 D 2029-04-14 Common Stock 42000 275988 D Stock Option (right to buy) 1.39 2021-12-28 4 M 0 6693 0.00 D 2029-04-14 Common Stock 6693 269295 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.86 to $41.74, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.84 to $42.49, inclusive. The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023. /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan 2021-12-29